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Diffuse Optical Monitoring of Blood Flow and Oxygenation in Human Breast
Cancer During Early Stages of Neoadjuvant Chemotherapy
Abstract
We combine diffuse optical spectroscopy (DOS) and diffuse correlation spectroscopy (DCS) to
noninvasively monitor early hemodynamic response to neoadjuvant chemotherapy in a breast cancer
patient. The potential for early treatment monitoring is demonstrated. Within the first week of treatment
(day 7) DOS revealed significant changes in tumor/normal contrast compared to pretreatment (day 0)
tissue concentrations of deoxyhemoglobin (rctHHbT/N=69±21%), oxyhemoglobin (rctO2HbT/N=73±25%),
total hemoglobin (rctTHbT/N=72±17%), and lipid concentration (rctLipidT/N=116±13%). Similarly, DCS
found significant changes in tumor/normal blood flow contrast (rBFT/N=75±7% on day 7 with respect to
day 0). Our observation suggest the combination of DCS and DOS enhances treatment monitoring
compared to either technique alone. The hybrid approach also enables construction of indices reflecting
tissue metabolic rate of oxygen, which may provide new insights about therapy mechanisms.
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Abstract. We combine diffuse optical spectroscopy 共DOS兲 and diffuse correlation spectroscopy 共DCS兲 to noninvasively monitor early
hemodynamic response to neoadjuvant chemotherapy in a breast
cancer patient. The potential for early treatment monitoring is demonstrated. Within the first week of treatment 共day 7兲 DOS revealed
significant changes in tumor/normal contrast compared to pretreatment 共day 0兲 tissue concentrations of deoxyhemoglobin 共rctHHbT/N
= 69± 21% 兲, oxyhemoglobin 共rctO2HbT/N = 73± 25% 兲, total hemoglobin 共rctTHbT/N = 72± 17% 兲, and lipid concentration 共rctLipidT/N
= 116± 13% 兲. Similarly, DCS found significant changes in tumor/
normal blood flow contrast 共rBFT/N = 75± 7% on day 7 with respect to
day 0兲. Our observations suggest the combination of DCS and DOS
enhances treatment monitoring compared to either technique alone.
The hybrid approach also enables construction of indices reflecting
tissue metabolic rate of oxygen, which may provide new insights
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1

Introduction

Near-infrared 共NIR兲 diffuse optical spectroscopy 共DOS兲 and
tomography 共DOT兲 have been employed quantitatively by
several groups to characterize breast cancers.1–10 In clinical
investigations, DOS and DOT have revealed tumor contrast in
total hemoglobin concentration,1,4,6–9,11–17 hemoglobin oxygen
saturation,4,11,12,14,17 water and lipid concentration,14,17,18 and
tissue scattering.2,16,18 Furthermore, DOS and DOT have also
shown promise for therapeutic monitoring of breast cancer
Address all correspondence to: Chao Zhou, University of Pennsylvania, Department of Physics & Astronomy, 209 S. 33rd St., Philadelphia, PA, 19104; Tel:
215-898-8422; Fax: 215-573-6391; E-mail: chaozhou@alumni.upenn.edu
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patients.14–17,19,20 Studies during neoadjuvant chemotherapy
共chemotherapy prior to surgery兲 have shown that tumor metabolic response can precede anatomical changes 共e.g., size兲
accessible to traditional imaging and clinical palpation
methods.21 Thus, new diagnostic methodologies focusing on
physiological properties of the tumor, for example, hemodynamic response, may offer benefits beyond those of traditional
imaging and palpation during the early course of chemotherapy. In a recent case study, for example, Jakubowski
et al.14 used DOS and observed significant changes in total
1083-3668/2007/12共5兲/051903/11/$25.00 © 2007 SPIE
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hemoglobin concentration and water fraction within 5 days of
the start of treatment.
Another important hemodynamic parameter is blood flow.
Measurements of blood flow provide insight about oxygen
delivery and the clearance of metabolic by-products, complementary to information about tissue chromophores and scattering available to DOS. In vivo diffuse optical measurement
of blood flow has recently been explored using diffuse correlation spectroscopy22–25 共DCS兲 in brain,26–31 muscle,32,33 and
in the tumor tissues34–37 of animal models and humans. A
recent DCS study in human breast tumors37 showed increased
blood flow contrast in tumor regions relative to adjacent
healthy tissue, consistent with results from ultrasound,38 positron emission tomography39 共PET兲, and magnetic resonance
imaging40 共MRI兲. In some cases, the DCS technique has been
validated33,34 with ultrasound and MRI, and in a few cases the
therapy monitoring capability of hybrid DCS/DOS instruments has been demonstrated.34–36 The latter instruments are
particularly exciting because, in principle, the oxygen delivery information derived from blood flow can be used in combination with blood oxygenation measurements to estimate
the metabolic rate of oxygen consumption in tissue.
In this paper, we describe a case study of a breast cancer
patient during the early stages of neoadjuvant chemotherapy.
In contrast to previous optical measurements of breast tumors,
the current work used both DOS and DCS in the same patient
to derive information about tumor chromophores, tumor scattering, and tumor blood flow. Significant changes in tissue
hemodynamic parameters were detected as early as 3 days
post-therapy. To date, several studies have focused on measurements of parameters related to cancer metabolism and
blood flow after few cycles of chemotherapy, i.e., after several
weeks.39,41–45 The present study has focused on daily measurements within the first week. The observations of blood
flow changes are the first of their kind during early stage
chemotherapy. The combined DOS/DCS information provides
a more complete picture of tumor tissue hemodynamics and
enables us to construct new indices reflecting changes in oxygen metabolism that require knowledge about flow and oxyand/or deoxyhemoglobin concentrations.

2

Materials and Methods

2.1 Protocol
The patient measurements were conducted at the Beckman
Laser Institute of the University of California, Irvine 共UCI兲,
and were approved by the Internal Review Board at UCI. The
subject was a 45-year-old premenopausal Caucasian woman
undergoing neoadjuvant chemotherapy treatment; she provided informed written consent for Human Subjects protocol
95-563. The patient was diagnosed by core biopsy revealing
invasive ductal carcinoma in the left breast. Clinical palpation
identified an 11-cm⫻ 5-cm area at 3 o’clock 关Fig. 1共a兲兴. Dynamic contrast-enhanced MRI 共DCE-MRI兲 detected several
strongly enhanced masses within this area. The outer edge of
the tumor was located 0.5 to 1 cm underneath the skin. In
addition, the patient had multiple benign lesions at 1 o’clock
共by ultrasound兲. The tumor position was identified by palpation and ultrasound and was marked with a surgical pen to
ensure the scans on different days were performed at the same
location. The surgical pen marks were visible after day 3, and
Journal of Biomedical Optics

Fig. 1 共a兲 Tumor position and line-scan directions. Starting from point
1 in the upper outer quadrant, optical measurements were performed
at 1-cm intervals, ending at point 10 in the lower outer quadrant. 共b兲
Illustration of the line scans over the tumor. 共c兲 Timing diagram for
chemotherapy monitoring.

they were redrawn every day afterward. The accuracy for redrawing was within 2 to 3 mm. The optical probe repositioning accuracy was of similar order 共i.e., 2 to 3 mm兲. Measurements were made with the patient in the supine position. DOS
and DCS measurements were acquired using handheld probes
at 10 discrete points in a line along the curved surface at 1-cm
intervals across the tumor and surrounding tissue 共“line
scan”兲. The same measurement pattern was used on the contralateral breast for comparison. Figures 1共a兲 and 1共b兲 show
the tumor position and line-scan directions on the patient,
where the tumor center was located at the 5-cm position. One
line scan took about 10 共8兲 min per breast for DOS 共DCS兲,
respectively, resulting in a measurement time of about 40 min
per session. Extra care was taken during the DCS measurement to gently press the probe on the patient’s breast; the
operator attempted to keep that pressure relatively constant
and the probe stable.
The patient was treated with neoadjuvant chemotherapy
delivered in multiple stages. The initial treatment stage consisted of doxorubicin 共Adriamycin兲 and cyclophosphamide
共Cytoxan, A/C兲 therapy. A/C treatments were administered
once per cycle for four cycles, with each cycle lasting 2
weeks. Doxorubicin is a cytoxic anthracycline antibiotic, and
its mechanism of action is thought to prevent DNA and possibly RNA synthesis by intercalation. Doxorubicin was administered at a dose of 60 mg/ m2 once per cycle. Cyclophos-
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phamide is biotransformed principally in the liver to activate
alkylating metabolites, which cross-link to tumor cell DNA.
Cyclophosphamide was administered at a dose of 600 mg/ m2
once per cycle. DOS and DCS measurements were performed
on the same day prior to the therapy 共day 0兲, and every day
between 3 to 7 days after the first A/C cycle 关day 3 to day 7,
Fig. 1共c兲兴. Additional stages using other therapies were administered, but no DOS/DCS measurements were recorded
during these treatment stages 共DOS/DCS measurements
ended on day 7兲. The most relevant radiologic assessment was
the DCE-MRI study done 12 days after the first A/C therapy,
which showed shrinkage of multiple lesions, the largest lesion
of which shrunk by 1.7 cm 共in diameter兲. Ultrasound measurements were performed after the completion of all four
A/C cycles 共8 weeks兲 and detected an irregular hypoechoic
lesion of 1.3 cm in diameter, indicating a partial response to
A/C therapy. At the end of chemotherapy, DCE-MRI showed
several tiny enhanced foci. The surgical pathology from
lumpectomy at the conclusion of chemotherapy revealed residual intraductal and invasive ductal carcinoma with extensive fibrosis.

2.2 Instrumentation
2.2.1 DOS
A broadband DOS system developed46 at UCI was utilized to
determine tissue optical properties and tissue blood oxygenation in vivo. The system combined a steady state 共SS兲
tungsten-halogen light source and spectrophotometer operating in the 600 to 1000-nm range and a frequency-domain
photon migration 共FDPM兲 component 共based on a network
analyzer兲 consisting of six laser diodes 共operating at discrete
wavelengths in the 660 to 850-nm range兲. The combination of
the cw and discrete spectral components enabled determination of complete a and s⬘ spectra from 600 to 1000 nm.
Measurements were made using a handheld probe consisting
of the SS and FDPM source fibers, one avalanche photodiode
共APD兲 detector and one spectrometer detector fiber. The
source-detector separation was 2.8 cm and the time to perform SS and FDPM measurements at a single position was
typically about 30 to 45 s. A detailed description of the performance of this device in 58 breast cancer patients has recently been reported.10
2.2.2 DCS
A portable two-channel DCS instrument 共18⫻ 28⫻ 33 cm兲
was built at the University of Pennsylvania and transported to
UCI for the measurements of blood flow. Briefly, a compact
cw 785-nm long coherence laser 共coherence length ⬃50 m,
Crystalaser, Reno, Nevada兲 was used as the light source. Two
fast-photon-counting APDs 共Perkin-Elmer, Canada兲 were
used to register the photons collected with single-mode fibers.
A custom-built two-channel correlator board 共www.correlator.com, New Jersey兲 took the transistor-to-transistor logic
共TTL兲 output from the APDs and calculated normalized temporal intensity autocorrelation functions of the detected light,
g2共兲 = 具I共t兲I共t + 兲典 / 具I共t兲典2, where I共t兲 is the measured intensity at time t,  is the correlation delay time, and the angle
brackets 具典 denote an average over time. A single source fiber
and two detector fibers were used in the handheld probe with
2.5-cm source-detector separations. Thus, the DCS measureJournal of Biomedical Optics

ment probed approximately the same volume of breast tissue
as the DOS measurement and a typical photon count rate of
⬃30 kHz was obtained from the breast measurement. Each
temporal autocorrelation curve was averaged for 2.5 s, and
multiple DCS measurements 共typically ⬎10兲 were performed
at a single position to ensure a good signal-to-noise ratio
共SNR兲.

2.3 Data Analysis
2.3.1 DOS Measurements
The algorithm for analyzing the DOS data was described in
detail by Bevilacqua et al.46 Briefly, the frequency domain
measurements at six discrete wavelengths were used to extract
the reduced scattering coefficient 共s⬘兲 at each wavelength. A
power law function,47–49 s⬘共兲 = A−b, was then fit to the
wavelength-dependent s⬘ to estimate the scattering information at all other wavelengths. With s⬘共兲 input from the
frequency-domain measurements, the data measured with the
spectrometer system was employed to extract accurate absorption coefficients a⬘共兲 over the whole spectral range. As
a result, tissue concentrations of oxy-, deoxy-, and total hemoglobin 共ctO2Hb, ctHHb and ctTHb兲, water 共ctH2O兲 and
lipid 共ctLipid兲 were reconstructed by decomposing the absorption spectra.46 Note that our notation is designed to comply with Zander and Mertzlufft,50 where the prefix “ct” indicates tissue-level concentration 共see Table1兲.
2.3.2 DCS Measurements
We used the intensity temporal autocorrelation curves measured with the DCS instrument to extract tissue blood flow
information. The decay rate of the correlation curves is correlated with the blood flow, e.g., faster decay reflects higher
blood flow. In our analysis, the photon correlation diffusion
equation24,25 was used to model the propagation of the electric
field autocorrelation function, G1共r , 兲 = 具E共r , t兲E*共r , t + 兲典,
inside tissues,

冋

册

1
ⵜ关D ⵜ G1共r, 兲兴 − v⬘a + vs⬘k20␣具⌬r2共兲典 G1共r, 兲 =
3
− v S ␦ 3共 r − r s兲 .

共1兲

Here, E共r , t兲 is the electric field at position r and time t,  is
the correlation delay time, v is the light speed in the media,
D ⬵ v / 3s⬘ is the light diffusion constant, k0 is the optical
wave vector, 具⌬r2共兲典 is the mean-square displacement of the
moving scatters in time , and S␦3共r − rs兲 is the point source
term located at rs. The normalized electric field autocorrelation function g1共r , 兲 = G1共r , 兲 / G1共r , 0兲 is related to the
measured intensity autocorrelation function g2共r , 兲 through
the Siegert relation51:

g2共r, 兲 = 1 + ␤兩g1共r, 兲兩2 ,

共2兲

where ␤ depends on the detection optics 共e.g., it is inversely
proportional to the number of detected speckles兲. We determined ␤ for each measurement. The decay of the correlation
function depends on tissue a and s⬘, the mean square displacement 具⌬r2共兲典, of the moving scatterers inside the tissue,
and a unitless factor ␣ that represents the fraction of scatterers
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Table 1 Table of abbreviations.
Name

Symbol

Units

Deoxy-hemoglobin concentration

ctHHb

M

Oxy-hemoglobin concentration

ctO2Hb

M

Total hemoglobin concentration

ctTHb

M

Hemoglobin oxygen saturation

stO2

%

Water concentration

ctH2O

% 共with respect to pure substance兲

Lipid concentration

ctLipid

% 共with respect to pure substance兲

Blood flow index

BFI

cm2 / s

Tissue optical index

TOI

M

MMRO2

M / 100 g min−1

T/N

folds

r

%

Mammary metabolic rate of oxygen
Tumor/normal contrast
Relative change compared to day 0

Notes on nomenclature: 共1兲 a prefix ct indicates tissue-level concentration of the parameter; 共2兲 subscripts T and N indicate values of tumor and normal tissues,
respectively, where a subscript T / N indicates the tumor/normal contrast; 共3兲 a prefix r indicates relative change compared to prechemotherapy value 共day 0兲.

that are moving 共i.e., red blood cells兲. A semi-infinite solution
to Eq. 共1兲 共Ref. 25兲 was used in our data analysis. We have
observed that a diffusion model, i.e., 具⌬r2共兲典 = 6Db, fits the
autocorrelation curves rather well over a broad range of tissue
types, including the present experiments.26,32,34,52 Here, Db is
the effective Brownian motion coefficient of the scatterers
共distinct from the well known thermal Brownian motion coefficient due originally to Einstein53兲. Although the units of
␣Db 共square centimeters per second兲 is different from the traditional blood perfusion unit 共milliliters per minute per
100 g兲, we have verified that changes in ␣Db are proportional
to the changes in tissue blood flow in a wide range of
measurements.32–34,52,54 Determination of ␣ is difficult. Therefore in the current study, we report ␣Db as the blood flow
index 共BFI= ␣Db兲. Bulk optical properties of the breast, a
and s⬘ at 785 nm, were obtained from the DOS measurements and used in the DCS data analysis to minimize the
influence of optical property changes on the accuracy of BFI.
In our fitting process, the noise in the correlation curve 共兲
was estimated as a function of delay time , and was used in
calculating 2, e.g., 2 = 储g2m共兲 − g2c共兲 / 共兲储, where g2m共兲
and g2c共兲 are the measured and calculated intensity autocorrelation curves, respectively. A more stable BFI is usually
obtained from the fitting by minimizing 2 as defined in this
way.30

2.3.3 Tissue Optical Index
The tissue optical index 共TOI兲 is a multiparameter contrast
function created to maximize both the contrast and the specificity of the optical measurement. The TOI is defined as10,19
ctHHb · ctH2O
.
ctLipid

TOI =
Journal of Biomedical Optics

共3兲

The parameters in this contrast function were chosen based
on a statistical study of 58 malignant breast lesions.10 In this
study, deoxy-hemoglobin was identified as the single best discriminator between malignant tumors and normal tissue, and
it was found that addition of water and lipid concentrations
further improved malignant/normal discrimination. The simplest index combining these parameters used ctHHb and
ctH2O in the numerator and ctLipid in the denominator. As
such, increased TOI reflects a higher chance of tumor malignancy. Conceptually, the TOI takes into account functional
共ctHHb and ctH2O兲 and structural 共ctLipid and ctH2O兲 information. TOI is also related to metabolic activity since increases in deoxy-hemoglobin are often a symptom of unmet
metabolic demand.

2.3.4 Oxygen Metabolism
Another, and perhaps more direct, estimate of tissue oxygen
metabolism can be calculated by combining information
about blood flow 共delivery of oxygen兲 measured by DCS with
chromophore concentration information such as blood oxygen
saturation 共i.e., oxygen availability兲 measured by DOS. This
approach is often employed in studies of cerebral metabolic
rate of oxygen55–60 共CMRO2兲. In the simplest model,
CMRO2 is proportional to the tissue arterial-venous oxygenation difference or oxygen extraction fraction 共OEF兲 as well
as the rate of oxygen delivery 共i.e., the cerebral blood flow,
CBF兲. Several assumptions are typically made in the steadystate model, including constant vasculature compartmentalization. The CMRO2 model has been fairly well studied, validated and its limits examined.27,28,55–61
In this paper, we construct a mammary oxygen metabolism
model that closely follows the CMRO2 approach in brain 共see
the appendix兲. We define the tumor/normal contrast of the
mammary metabolic rate of oxygen 共MMRO2共T/N兲兲 as,
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MMRO2共T/N兲 =

冉

␥T ctHHbT ctTHbT
·
·
␥N ctHHbN ctTHbN

冊

−1

·

BFIT
, 共4兲
BFIN

where T and N represent the values for tumor and normal
breast tissue 共i.e., normal tissues within the same breast兲, and
␥T共N兲 = 关ctHHbvT共N兲 / ctTHbvT共N兲兴 / 关ctHHbT共N兲 / ctTHbT共N兲兴 is
the ratio of tumor 共or normal兲 deoxy-to total-hemoglobin in
the venous compartment 共v兲 compared to the ratio of deoxy-to
total-hemoglobin in the total vasculature 共see the appendix兲.
The simplest approximation, which we adopt here, assumes
the ratio of ␥T / ␥N to be 1 and constant over time. The relative
tumor/normal contrast of mammary metabolic rate of oxygen
共rMMRO2共T/N兲, see Table 1兲 can now be estimated from our
measurements. We note, however, that these assumptions are
unverified. The precise quantification of ␥T and ␥N requires
better understanding of the microcirculation in tumor and normal tissues, and such precision is beyond the scope of the
current study.

2.3.5 Characterization of Responses
To quantify tumor response to chemotherapy, the tumor/
normal contrast for the parameters at each time point was
determined. Tumor/normal contrast was calculated as the ratio
of the average tumor value 共positions 3 to 7 in the line scans兲
to the average value of the normal tissue on the same side of
the breast 共i.e., positions 8 to 10兲, for example, BFT/N
= BFIT / BFIN, ctTHbT/N = ctTHbT / ctTHbN, etc. The positions
were chosen based on palpation, and positions 1 and 2 were
excluded as normal tissue because they were too close to
other benign lesions. This calculation effectively accounts for
the global variations in response to chemotherapy by normalizing to the daily normal tissue values. Thus, the tumor specific responses of each parameter are “pulled” out of the measurement. The tumor/normal contrast for each time point was
then normalized to prechemotherapy values 共day 0兲 to reflect
relative changes, indicated by a prefix “r” for each parameter
共see Table 1兲. Wilcoxon rank-sum tests were conducted comparing the optically measured differences between tumor and
normal on day 0. Significant changes were observed and
marked in the figures with an ‘*’, representing a significance
level of p ⬍ 0.05 compared to prechemotherapy values.

3

Results and Discussion

Figure 2 exhibits representative DCS temporal autocorrelation
curves measured on the tumor before and after the first A/C
treatment 共days 0, 3, and 7兲. The figure also shows data from
normal tissue from both breasts on day 0. The symbols are
raw data and the solid lines are fitted curves. The correlation
curves measured on the tumor have significantly faster decay
rates compared to those from normal breast tissues, indicating
higher blood flow in the tumor. The measurements from the
tumor on different days are clearly distinguishable from one
another with good SNR, thus enabling us to quantify tumor
blood flow changes due to chemotherapy.
Figure 3 shows line scans of blood flow index 关BFI
= ␣Db, Fig. 3共a兲兴 and total hemoglobin concentration 关ctTHb,
Fig. 3共b兲兴 from both the tumor breast and the contralateral
breast before and after the first chemotherapy treatment 共days
0, 3, and 7兲. Error bars in the figures represent the standard
deviation of repeated measurements. The measurements conJournal of Biomedical Optics

Fig. 2 Raw 共symbols兲 and fitted intensity autocorrelation curves 共solid
lines兲 measured from the patient before and after chemotherapy 共day
0, day 3, and day 7兲. Both ␤ and the BFI 共BFI= ␣Db兲 were fit. Similar
␤ values were obtained for both normal and tumor breast tissues. The
correlation curves measured on the tumor have larger decay rates
compared to the curves measured on the contralateral breast, indicating higher blood flow in the tumor.

ducted on different days were reproducible, which can be seen
from the scans on the contralateral breast and the normal tissues on the tumor-bearing breast 共positions 8 to 10兲. BFI exhibited significant increases in the tumor breast 共i.e.,
10.6± 1.8 folds兲 relative to the heterogeneity of normal breast
tissue on the contralateral side 共i.e., 2.1± 0.7兲. ctTHb also
showed clear tumor/normal contrast 共i.e., 2.1± 0.3兲. For clarity, line–scans for other hemodynamic parameters, such as
ctHHb, ctO2Hb, and water and lipid concentrations, are not
plotted. The observed tumor/normal contrast of these parameters is consistent with previous reports,10,14 i.e., ctHHb had a
contrast of 2.1± 0.2, ctO2Hb had a contrast of 2.0± 0.3, water
had a contrast of 1.9± 0.3, ctLipid had a contrast of 0.8± 0.05,
and s⬘ at 785 nm had a contrast of 0.96± 0.03 prior to the
A/C treatment.
Neoadjuvant chemotherapy can induce hemodynamic
changes in both tumor and normal tissues.14,16 To investigate
the tumor specific changes in response to the chemotherapy,
relative tumor/normal contrast of ctHHb, ctO2Hb, and ctTHb
with respect to pretherapy values 共rctHHbT/N, rctO2HbT/N,
and rctTHbT/N兲 were calculated and are plotted in Fig. 4.
Notice that significant changes in these hemodynamic parameters were observed as early as 4 days after the start of A/C
therapy 共p ⬍ 0.05兲, i.e. rctHHbT/N dropped to 68± 12% of its
original value 共day 0兲; rctO2HbT/N dropped to 63± 10%; and
rctTHbT/N dropped to 63± 10%. By the end of the monitoring
period 共day 7兲, there were continued small hemodynamic reductions and all values remained substantially lower than pretreatment levels 共day 0兲: rctHHbT/N dropped to 69± 21% 共p
⬍ 0.05兲; rctO2HbT/N dropped to 73± 25% 共p ⬍ 0.05兲; and
rctTHbT/N dropped to 72± 17% 共p ⬍ 0.05兲.
Relative tumor/normal contrast of blood flow 共rBFT/N兲,
concentration of water 共rctH2OT/N兲 and lipid 共rctLipidT/N兲,
⬘ 兴 in response to the
and reduced scattering coefficient 关rs共T/N兲
chemotherapy are plotted in Fig. 5. Blood flow measured with
DCS showed good SNR ratio and substantial tumor-to-normal
contrast. rBFT/N increased initially on day 3 after the A/C
therapy 共130± 13% , p ⬍ 0.05兲, followed by a sharp and sus-
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Fig. 4 Relative tumor/normal ctHHb, ctO2Hb, and ctTHb contrast
共rctHHbT/N, rctO2HbT/N and rctTHbT/N兲 in response to chemotherapy.
The contrasts were calculated as the ratio of the average tumor value
共positions 3 to 7 in the line scans兲 to the average value of the normal
tissue on the same side of the breast 共positions 8 to 10兲. The contrasts
were then normalized to the pre-chemotherapy values to reflect relative changes. Significant decreases in the contrast occurred in all three
parameters 4 days after the chemotherapy. Asterisks 共 *兲 denote the
data points significantly different from the pre-chemotherapy values
共day 0, p ⬍ 0.05兲. Plots were slightly offset along the x axis for better
illustration of the error bars.

Fig. 3 Line scans of 共a兲 BFI and 共b兲 ctTHb before and after the first
chemotherapy cycle 共day 0, day 3, and day 7兲. On the tumor side of
the breast, BFI showed clear contrast, which was much larger than the
heterogeneity of the breast tissue on the contralateral side. The ctTHb
also showed clear contrast on the tumor. Tumor contrasts changed in
response to the chemotherapy. For clarity, line scans of other hemodynamic parameters, such as ctHHb, ctO2Hb, and water and lipid
concentrations, are not plotted. Error bars represent the standard deviation of repeated measurements. Plots were slightly offset along the
x axis for better illustration of the error bars.

tained drop on days 4 共72± 7 % , p = 0.13兲, 5 共68± 7 % , p
⬍ 0.05兲, and 7 共75± 7 % , p = 0.13兲. rctLipidT/N increased significantly from day 5 共108± 6 % , p ⬍ 0.05兲 to day 7
共116± 13% , p ⬍ 0.05兲. Since the lipid concentration in tumor
was lower than in the normal breast tissues before the therapy,
the increase in rctLipidT/N suggests that lipid concentration in
⬘
at 785 nm
the tumor is normalized over time. The rs共T/N兲
had a small increase within the week 共⬍7 % , p ⬎ 0.05兲, despite the increase on day 5, which was significant
共106± 4 % , p ⬍ 0.05兲. No significant changes for the relative
contrast of water concentration 共rctH2OT/N兲 were observed
within the first week. However, the subject was also enrolled
in a separate study for DOS, wherein significant decrease in
water contrast was observed after 4 months 共i.e., rctH2OT/N
decreased to 68± 7 % , p ⬍ 0.01兲.
Note, the optical properties 共a and s⬘兲 of the breast tissue
at 785 nm were measured by the DOS instrument. Measured
absorption and scattering effects are incorporated into the
DCS data analysis. As a result, the influence of oxygenation
state of the breast should not influence our blood flow results.
On the other hand, probe contact pressure and the movement
Journal of Biomedical Optics

of fiber optics could have an effect on our DCS measurements. In a previous experiment,32 we have carried out tests
that suggest the movement of fiber optics do not influence the
DCS measurements after the optical probe was secured in
place. An indication that the pressure and motion effects are
minimal can be seen from the relatively small variations measured on the contralateral side of the breast 共Fig. 3兲, i.e., the

Fig. 5 Relative tumor/normal blood flow index, water, lipid and s⬘
⬘ 兲 in response to
contrast 共rBFT/N, rctH2OT/N, rctLipidT/N, and rs共T/N兲
chemotherapy. The contrasts were calculated as the ratio of the average tumor value 共positions 3 to 7 in the line scans兲 to the average
value of the normal tissue on the same side of the breast 共positions 8
to 10兲. The contrasts were then normalized to the pre-chemotherapy
values to reflect relative changes. rBFT/N showed an significant initial
increase 共p ⬍ 0.05兲 on day 3 and a significant decrease on day 5 共p
⬍ 0.05兲. Water contrast did not change significantly in response to the
chemotherapy, while lipid contrast increased significantly after day 5
共p ⬍ 0.05兲. Asterisks 共 *兲 denote the data points significantly different
from the pre-chemotherapy values 共day 0, p ⬍ 0.05兲. Plots were
slightly offset along the x axis for better illustration of the error bars.
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day-to-day tumor contrast and variation were large compared
to the combination of measurement noise, physiological
noise, motion artifact noise, and pressure related variations
experienced on the contralateral breast.
Chemotherapy treatment alters tumor angiogenesis.62
Therefore, optical properties of the tumor are expected to
change due to chemotherapy, which is observed in our measurements. Although chemotherapy may also induce changes
of other kinds of microscopic motions inside the tumor, we
believe such an effect is likely small compared to the changes
in tumor vasculature and blood flow. In our previous study of
photodynamic therapy treatment of mouse tumors,34 blood
flow changes measured with both ultrasound Doppler and
DCS showed comparable results, indicating the tumor responses measured with DCS are mainly due to blood flow.
The relative tumor blood flow reduction in response to neoadjuvant chemotherapy observed in the current study 共⬃25%
within the first week兲 is also consistent with results from PET
studies,39,63 wherein a 30% to 50% blood flow decrease after 2
months of chemotherapy was reported. Yet blood flow
changes exhibit distinct features compared to other hemodynamic parameters measured with DOS. For example, we have
observed an ⬃30% initial increase in rBFT/N on day 3 in this
patient 共Fig. 5兲, accompanied by an ⬃20% decrease in
rctHHbT/N 共Fig. 4兲. Although the mechanism is not clear, this
may be due to an early tumor vascular response to cellular
damage. The ⬃20% decrease in rctHHbT/N on day 3 could be
consistent with reduced oxygen extraction given that
rctTHbT/N remained roughly constant and flow was elevated.
By day 4, A/C therapy has continued to damage both cells and
vasculature; rBFT/N, rctHHbT/N, and rctHHbT/N all decreased
because of significant damage to tumor cells. A similar initial
increase followed by a significant decrease of blood flow was
observed during the first few days after radiation therapy in
patients with breast tumors.64 In patients with head and neck
tumors,36,65 and rectal carcinoma,66 similar patterns of blood
flow changes were also reported in the early weeks after radiation therapy. Further studies involving more patients are
underway to confirm the observations in this case study.
As described in Sec. 2.3, the combination of DCS and
DOS measurements enable oxygen metabolic changes in the
tumor to be calculated using Eq. 共4兲. Compared to flow, hemoglobin concentrations, and other tissue parameters alone,
this relative metabolism index is a potentially more direct
indicator of tumor metabolic activities that integrates many
factors and may provide further insight about tumor physiological responses to therapy. Figure 6 displays the relative
changes in tumor/normal contrast of mammary metabolic rate
of oxygen and the tissue optical index based on chromophore
concentrations 关i.e., rMMRO2共T/N兲 and rTOIT/N兴. Values of
relative tumor/normal contrast for all the optically derived
parameters are listed in Table 2. rMMRO2共T/N兲 and rTOIT/N
differed on day 3, e.g. rTOIT/N had an initial drop
共72± 16% , p = 0.13兲 and rMMRO2共T/N兲 had an initial increase 共118± 13% , p = 0.68兲, but both parameters were only
marginally different from day 0. The initial increase observed
in rMMRO2共T/N兲 is most probably a result of the initial increase of blood flow, although further evidence is needed for
this hypothesis to be confirmed. However, after day 4, both
metabolic indices dropped significantly 共rTOIT/N = 60± 9%,
Journal of Biomedical Optics

Fig. 6 Relative tumor/normal tissue optical index and mammary
metabolic rate of oxygen contrast 关rTOIT/N and rMMRO2共T/N兲兴 in response to chemotherapy. The contrasts were calculated as the ratio of
the average tumor value 共positions 3 to 7 in the line scans兲 to the
average value of the normal tissue on the same side of the breast
共positions 8 to 10兲. The contrasts were then normalized to the prechemotherapy values to reflect relative changes. Significant decreases
were observed in both rTOIT/N and rMMRO2共T/N兲 after day 4. Asterisks
共 *兲 denote the data points significantly different from the prechemotherapy values 共day 0, p ⬍ 0.05兲. Plots were slightly offset along
the x axis for better illustration of the error bars.

p ⬍ 0.05 and rMMRO2共T/N兲 = 78± 7%, p ⬍ 0.05 on day 4兲 and
then stabilized at this level until the end of the monitoring
period. We note that although both TOIT/N and MMRO2共T/N兲
are considered to be related to tumor metabolic responses,
TOIT/N provides information about tumor cellular metabolic
activities,19,67 while MMRO2共T/N兲 provides an estimation of
tumor oxygen metabolic changes. Note that tumors have abnormal vasculatures and the input and output circulations to
and from the tumor are not well characterized. Our assumption of saO2T = 1 共see the appendix兲 may not be true, but in
the absence of more information, we believe this is a reasonable starting assumption. MMRO2共T/N兲 共Eq. 共4兲兲 functions
more as a relative index of oxygen consumption than as a
quantitative measure of true oxygen metabolism. We have introduced MMRO2共T/N兲 as a potentially useful index for monitoring cancer physiology accessible to the optical method. Its
utility, however, must be determined by more clinical studies.
To date only a few in vivo studies on human tumors have
probed oxygen metabolism.68–71 Further studies and validation in animal models using methods presented in this paper
may be useful to improve the oxygen metabolism model in
tumors, to reveal the connections between TOI and oxygen
metabolism, and to provide potential diagnostics for chemotherapy efficacy.

4

Conclusion

We reported a case study wherein we monitored hemodynamic and tissue optical property changes in a breast tumor
patient undergoing neoadjuvant chemotherapy. Our approach
employed a combination of DOS and DCS to measure simultaneously blood oxygenation, lipid, water, and blood flow. We
demonstrated the feasibility of this methodology and detected
significant changes in tissue parameters as early as day 3 following the first chemotherapy infusion. This study introduced
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Table 2 Tumor/normal contrast changes normalized to day 0 values of all parameters within the first week of chemotherapy.
Day 0

Day 3

Day 4

Day 5

Day 6

Day 7

rctHHbT/N

1.00± 0.09

0.81± 0.12

0.68± 0 . 12*

0.71± 0 . 17*

0.72± 0 . 14*

0.69± 0 . 21*

rctO2HbT/N

1.00± 0.16

0.95± 0.17

0.63± 0 . 10*

0.75± 0 . 14*

1.00± 0.28

0.73± 0 . 25*

rctTHbT/N

1.00± 0.15

0.92± 0.16

0.63± 0 . 10*

0.75± 0 . 15*

0.94± 0.24

0.72± 0 . 17*

rctH2OT/N

1.00± 0.16

0.97± 0.14

1.02± 0.15

1.04± 0.16

1.01± 0.19

1.04± 0.22

rctLipidT/N

1.00± 0.06

1.04± 0.07

1.13± 0.08

1.08± 0 . 06*

1.19± 0 . 07*

1.16± 0 . 13*

rBFT/N

1.00± 0.17

1.30± 0 . 13*

0.72± 0.07

0.68± 0 . 07*

0.91± 0.10

0.75± 0.07

⬘
rs共T/N兲

1.00± 0.03

1.02± 0.05

1.04± 0.04

1.06± 0 . 04*

1.06± 0.03

1.07± 0.04

rTOIT/N

1.00± 0.16

0.72± 0.16

0.60± 0 . 09*

0.65± 0 . 23*

0.59± 0 . 13*

0.59± 0.18

1.00± 0.17

1.18± 0.13

0.78± 0.07

0.66± 0 . 08*

0.67± 0 . 11*

0.73± 0 . 11*

rMMRO2共T/N兲
*

Asterisks 共 兲 denote the data points significantly different from the prechemo therapy values 共day 0, p ⬍ 0.05兲.

optical measurement of blood flow as a new parameter for
therapy monitoring along with multiparameter indices that
may provide further physiological insight, such as tissue
metabolic rate of oxygen. Overall, the hybrid diffuse optical
approach shows promise for therapy monitoring, optimization, and personalization by potentially detecting physiological changes that may precede anatomical changes accessible
to traditional radiological diagnostics procedures.

MMRO2共T/N兲 =

saO2T − svO2T BFT saO2T − svO2T BFIT
=
,
saO2N − svO2N BFN saO2N − svO2N BFIN
共7兲

given the assumption that the changes of BFI are proportional
to the changes of tissue blood flow 共see Sec. 2.3兲. Assuming
saO2T = saO2N = 1, we will have

MMRO2共T/N兲 =

Appendix
In this section, we derive the equation for the calculation of
the tumor/normal contrast of the mammary metabolic rate of
oxygen 关MMRO2共T/N兲兴 following the steps in deriving the
cerebral metabolic rate of oxygen 共CMRO2兲.27,55–60
Using Fick’s law, the tumor 共or normal兲 mammary metabolic rate of oxygen 关MMRO2T共N兲兴 can be calculated as

MMRO2T共N兲 = OEFT共N兲 · BFT共N兲 · 关O2兴aT共N兲 .

共5兲

The tumor 共or normal兲 oxygen extraction factor 关OEFT共N兲兴
is by definition the fractional conversion of oxygen from arterioles
to
venules,
i.e.,
OEFT共N兲 = 共关O2兴aT共N兲
− 关O2兴vT共N兲兲 / 关O2兴aT共N兲, where 关O2兴aT共N兲 and 关O2兴vT共N兲 are the
tumor 共or normal兲 arteriolar and venous concentrations of
oxygen. BFT共N兲 is the tumor 共or normal兲 blood flow. In
steady-state, assuming a balance between oxygen concentration and oxyhemoglobin saturation in the arteriolar and
venous compartments 关saO2T共N兲 and svO2T共N兲兴, we have

OEFT · 关O2兴aT 关O2兴aT − 关O2兴vT saO2T − svO2T
=
=
. 共6兲
OEFN · 关O2兴aN 关O2兴aN − 关O2兴vN saO2N − svO2N
As a result, the tumor/normal contrast of mammary metabolic rate of oxygen 关MMRO2共T/N兲兴 can be expressed as
Journal of Biomedical Optics

1 − svO2T BFIT
·
1 − svO2N BFIN

=

共ctHHbvT/ctTHbvT兲 BFIT
共ctHHbvN/ctTHbvN兲 BFIN

=

ctHHbvT ctTHbvT
ctHHbvN ctTHbvN

冉

冊

−1

BFIT
.
BFIN

共8兲

The diffuse optical signal originates from the hemoglobin
in the tissue within the view of the probe, and represents a
mixture of arterial, capillary and venous blood. The mixed
tissue compartment 共MTC兲 viewed by the optical probe is a
weighted average of the arterial 共a兲, capillary 共c兲, and venous
共v兲 compartments, and the weight is proportional to the optical cross section of the corresponding compartment. For example, ctHHb= k1 · ctHHba + k2 · ctHHbc + k3 · ctHHbv, where
k1, k2, and k3 are the respective weights and k1 + k2 + k3 = 1. If
we further assume the quantities in the venous compartment
are proportional to the MTC values, i.e.,

ctHHbvT = r1T · ctHHbT,ctTHbvT = r2T · ctTHbT ,
ctHHbvN = r1N · ctHHbN,ctTHbvN = r2N · ctTHbN .

共9兲

We can further simplify by defining ␥T共N兲 = r1T共N兲 / r2T共N兲
= 关ctHHbvT共N兲 / ctHHbT共N兲兴 / 关ctTHbvT共N兲 / ctTHbT共N兲兴
= 关ctHHbvT共N兲 / ctTHbvT共N兲兴 / 关ctHHbT共N兲 / ctTHbT共N兲兴, which
is the ratio of deoxy to total hemoglobin in the venous com-
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partment compared to the ratio of deoxy to total hemoglobin
in the total mixed vasculature. As a result, we will have

MMRO2共T/N兲 =

冉

r1T · ctHHbT r2T · ctTHbT
r1N · ctHHbN r2N · ctTHbN

冉

r1T/r2T ctHHbT ctTHbT
=
r1N/r2N ctHHbN ctTHbN
=

冉

␥T ctHHbT ctTHbT
␥N ctHHbN ctTHbN

冊

−1

冊

冊

−1

−1

11.

BFIT
BFIN

12.

BFIT
BFIN

BFIT
,
BFIN

13.

共10兲

where ␥T and ␥N are two unknowns. The ratio of ␥T / ␥N
reflects the relative oxygen extraction ability of the vasculature. For example, a ␥T / ␥N ratio larger than 1 means a higher
tumor deoxyhemoglobin fraction in the venous compartment
relative to the total mixed vasculature compared to the normal
tissue, reflecting a larger portion of oxygen is extracted from
the tumor tissue.
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